Cargando…
Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
Ovarian cancer remains the most fatal gynecologic malignancy worldwide due to delayed diagnosis as well as recurrence and drug resistance. Thus, the development of new tumor-related molecules with high sensitivity and specificity to replace or supplement existing tools is urgently needed. Cancer-tes...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318940/ https://www.ncbi.nlm.nih.gov/pubmed/30609934 http://dx.doi.org/10.1186/s13048-018-0475-z |
_version_ | 1783384976491806720 |
---|---|
author | Xie, Kaipeng Fu, Chenyang Wang, Suli Xu, Hanzi Liu, Siyu Shao, Yang Gong, Zhen Wu, Xiaoli Xu, Bo Han, Jing Xu, Juan Xu, Pengfei Jia, Xuemei Wu, Jiangping |
author_facet | Xie, Kaipeng Fu, Chenyang Wang, Suli Xu, Hanzi Liu, Siyu Shao, Yang Gong, Zhen Wu, Xiaoli Xu, Bo Han, Jing Xu, Juan Xu, Pengfei Jia, Xuemei Wu, Jiangping |
author_sort | Xie, Kaipeng |
collection | PubMed |
description | Ovarian cancer remains the most fatal gynecologic malignancy worldwide due to delayed diagnosis as well as recurrence and drug resistance. Thus, the development of new tumor-related molecules with high sensitivity and specificity to replace or supplement existing tools is urgently needed. Cancer-testis antigens (CTAs) are exclusively expressed in normal testis tissues but abundantly found in several types of cancers, including ovarian cancer. Numerous novel CTAs have been identified by high-throughput sequencing techniques, and some aberrantly expressed CTAs are associated with ovarian cancer initiation, clinical outcomes and chemotherapy resistance. More importantly, CTAs are immunogenic and may be novel targets for antigen-specific immunotherapy in ovarian cancer. In this review, we attempt to characterize the expression of candidate CTAs in ovarian cancer and their clinical significance as biomarkers, activation mechanisms, function in malignant phenotypes and applications in immunotherapy. |
format | Online Article Text |
id | pubmed-6318940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-63189402019-01-08 Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets Xie, Kaipeng Fu, Chenyang Wang, Suli Xu, Hanzi Liu, Siyu Shao, Yang Gong, Zhen Wu, Xiaoli Xu, Bo Han, Jing Xu, Juan Xu, Pengfei Jia, Xuemei Wu, Jiangping J Ovarian Res Review Ovarian cancer remains the most fatal gynecologic malignancy worldwide due to delayed diagnosis as well as recurrence and drug resistance. Thus, the development of new tumor-related molecules with high sensitivity and specificity to replace or supplement existing tools is urgently needed. Cancer-testis antigens (CTAs) are exclusively expressed in normal testis tissues but abundantly found in several types of cancers, including ovarian cancer. Numerous novel CTAs have been identified by high-throughput sequencing techniques, and some aberrantly expressed CTAs are associated with ovarian cancer initiation, clinical outcomes and chemotherapy resistance. More importantly, CTAs are immunogenic and may be novel targets for antigen-specific immunotherapy in ovarian cancer. In this review, we attempt to characterize the expression of candidate CTAs in ovarian cancer and their clinical significance as biomarkers, activation mechanisms, function in malignant phenotypes and applications in immunotherapy. BioMed Central 2019-01-04 /pmc/articles/PMC6318940/ /pubmed/30609934 http://dx.doi.org/10.1186/s13048-018-0475-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Xie, Kaipeng Fu, Chenyang Wang, Suli Xu, Hanzi Liu, Siyu Shao, Yang Gong, Zhen Wu, Xiaoli Xu, Bo Han, Jing Xu, Juan Xu, Pengfei Jia, Xuemei Wu, Jiangping Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
title | Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
title_full | Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
title_fullStr | Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
title_full_unstemmed | Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
title_short | Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
title_sort | cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318940/ https://www.ncbi.nlm.nih.gov/pubmed/30609934 http://dx.doi.org/10.1186/s13048-018-0475-z |
work_keys_str_mv | AT xiekaipeng cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT fuchenyang cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT wangsuli cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT xuhanzi cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT liusiyu cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT shaoyang cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT gongzhen cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT wuxiaoli cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT xubo cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT hanjing cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT xujuan cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT xupengfei cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT jiaxuemei cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets AT wujiangping cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets |